Marta Malgorzata Wawrzynowicz-Syczewska

Prof. Dr. Marta Malgorzata Wawrzynowicz-Syczewska

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Marek DrozdzikMarek Drozdzik
Marek Drozdzik
JŁJoanna Łapczuk-Romańska
Joanna Łapczuk-Romańska
CWChristoph Wenzel
Christoph Wenzel
ŁSŁukasz Skalski
Łukasz Skalski
SSSylwia Sylwia Szeląg-Pieniek
Sylwia Sylwia Szeląg-Pieniek
SOStefan Oswald
Stefan Oswald
Transmembrane drug transport in hepatocytes is one of the major determinants of drug pharmacokinetics. In the present study, ABC transporters (P-gp, MRP1, MRP2, MRP3, MRP4, BCRP, and BSEP) and SLC transporters (MCT1, NTCP, OAT2, OATP1B1, OATP1B3, OATP2B1, OCT1, and OCT3) were quantified for protein abundance (LC-MS/MS) and mRNA levels (qRT-PCR) in hepatitis C virus (HCV)-infected liver samples from the Child–Pugh class A (n = 30), B (n = 21), and C (n = 7) patients. Protein levels of BSEP, MRP3, MCT1, OAT2, OATP1B3, and OCT3 were not significantly affected by HCV infection. P-gp, MRP1, BCRP, and OATP1B3 protein abundances were upregulated, whereas those of MRP2, MRP4, NTCP, OATP2B1, and OCT1 were downregulated in all HCV samples. The observed changes started to be seen in the Child–Pugh class A livers, i.e., upregulation of P-gp and MRP1 and downregulation of MRP2, MRP4, BCRP, and OATP1B3. In the case of NTCP, OATP2B1, and OCT1, a decrease in the protein levels was observed in the class B livers. In the class C livers, no other changes were noted than those in the class A and B patients. The results of the study demonstrate that drug transporter protein abundances are affected by the functional state of the liver in hepatitis C patients.

1 January 2013
Verified
Journal Article
Closed access
APAnatol Panasiuk
Anatol Panasiuk
Robert FlisiakRobert Flisiak
Robert Flisiak
IMIwona Mozer-Lisewska
Iwona Mozer-Lisewska
AAAgnieszka Adamek
Agnieszka Adamek
MTMałgorzata Tyczyno
Małgorzata Tyczyno
ALAnna Lachowicz
Anna Lachowicz

Verified
Journal Article
Open access
PDF file
Marek DrozdzikMarek Drozdzik
Marek Drozdzik
JŁJoanna Łapczuk-Romańska
Joanna Łapczuk-Romańska
CWChristoph Wenzel
Christoph Wenzel
ŁSŁukasz Skalski
Łukasz Skalski
SSSylwia Sylwia Szeląg-Pieniek
Sylwia Sylwia Szeląg-Pieniek
SOStefan Oswald
Stefan Oswald
Hepatic drug metabolizing enzymes (DMEs), whose activity may be affected by liver diseases, are major determinants of drug pharmacokinetics. Hepatitis C liver samples in different functional states, i.e., the Child–Pugh class A (n = 30), B (n = 21) and C (n = 7) were analyzed for protein abundances (LC-MS/MS) and mRNA levels (qRT-PCR) of 9 CYPs and 4 UGTs enzymes. The protein levels of CYP1A1, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 were not affected by the disease. In the Child–Pugh class A livers, a significant up-regulation of UGT1A1 (to 163% of the controls) was observed. The Child–Pugh class B was associated with down-regulation of the protein abundance of CYP2C19 (to 38% of the controls), CYP2E1 (to 54%), CYP3A4 (to 33%), UGT1A3 (to 69%), and UGT2B7 (to 56%). In the Child–Pugh class C livers, CYP1A2 was found to be reduced (to 52%). A significant trend in down-regulation of the protein abundance was documented for CYP1A2, CYP2C9, CYP3A4, CYP2E1, UGT2B7, and UGT2B15. The results of the study demonstrate that DMEs protein abundances in the liver are affected by hepatitis C virus infection and depend on the severity of the disease.

9 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HWHanna Wiśniewska
Hanna Wiśniewska
Karolina Skonieczna-ŻydeckaKarolina Skonieczna-Żydecka
Karolina Skonieczna-Żydecka
MPMiłosz Parczewski
Miłosz Parczewski
JNJolanta Niścigorska-Olsen
Jolanta Niścigorska-Olsen
EKEwa Karpińska
Ewa Karpińska
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
Liver injury—expressed as elevated liver enzymes—is common in patients with COVID-19. Little is known about the potential mechanisms of liver damage by SARS-CoV-2. A direct cytopathic effect on hepatocytes as well as injury related to hypoxia or hepatotoxicity are being considered. The aim of the study was to compare the clinical characteristic of COVID-19 disease in patients with normal and abnormal liver enzymes activity. A group of 150 patients with COVID-19, hospitalized in our center, was analyzed. Patients with the known liver comorbidities were excluded (n = 15). Clinical features and laboratory parameters were compared between patients with normal and abnormal aminotransferase values. Liver injury expressed as any alanine aminotransferase (ALT) elevation was noted in 45.6% of patients hospitalized due to COVID-19. The frequencies of aspartate aminotransferase (AST) elevation were lower. It was noted that elevated ALT/AST unfavorably affected other parameters related to liver function such as albumin level; gamma-glutamyl transpeptidase (GGTP); and partly, ALP activity and influenced inflammation-related parameters. The most probable cause of mild hepatitis during COVID-19 was anoxia and immune-mediated damage due to the inflammatory response following SARS-CoV-2 infection. A direct cytopathic effect of SARS-CoV-2 on hepatocytes, albeit less probable, can be considered as well. The use of potentially hepatotoxic drugs may contribute to liver damage.

1 August 2009
Verified
Journal Article
Closed access
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
EKEwa Karpińska
Ewa Karpińska
KJKrzysztof Jurczyk
Krzysztof Jurczyk
LLLukasz Laurans
Lukasz Laurans
ABAnna Boroń-Kaczmarska
Anna Boroń-Kaczmarska

1 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Paweł RajewskiPaweł Rajewski
Paweł Rajewski
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
EJEwa Janczewska
Ewa Janczewska
AGAndrzej Gietka
Andrzej Gietka
WMWłodzimerz Mazur
Włodzimerz Mazur
Robert FlisiakRobert Flisiak
Robert Flisiak
Hepatitis C infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, more and more is being heard about extrahepatic manifestations of the hepatitis C infection including its possible influence on the development of hypertension and cardiovascular diseases. In the given work, the frequency analysis of the incidence of hypertension and cardiovascular diseases among 2898 HCV-infected patients treated in Poland and the assessment of their relevance to the HCV genotype and the progression of liver fibrosis can be found. The prevalence of hypertension in the group of analyzed patients was 39% and was significantly associated with old age (OR = 1.08 (1.07–1.08)) and female sex, as well as the progression of liver fibrosis (OR = 1.54 (1.29–1.85)). Hypertension was found in 47.6% of patients with F4 fibrosis, 42.1% of patients with F3 fibrosis, and 25% of patients with F1 fibrosis. The incidence of cardiovascular disease in the studied group of patients was as follows: all incidents, 131 (4.52%); including ischemic heart disease 104, (3.95%); stroke, 2 (0.07%); atherosclerosis, 21 (0.72%); and aneurysms, 4 (0.14%). The obtained results prove that the prevalence of cardiovascular diseases is significantly associated with the advanced age of patients and the progression of liver fibrosis. The relevance of sex and the HCV genotype to the prevalence frequency of cardiovascular diseases in the study group has not been proven. This being the case, no differences in the frequency of their incidence depending on the HCV genotype, including genotype 3, was found. Hepatitis C infection as a non-classical risk factor for cardiovascular disease and hypertension does require further studying.